Janssen inks mega-deal with Japan’s PeptiDream
Janssen Pharmaceuticals has signed up for access to PeptiDream’s peptide discovery technology in a deal that could be worth $1.15 billion.
Read More
Tag: PeptiDream
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
